Munich Reinsurance Co Stock Corp in Munich Raises Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• Munich Re increased its Bristol Myers Squibb stake by 9.8% in the second quarter, bringing its holdings to 347,582 shares valued at approximately $20.0 million. Institutional investors collectively own 76.41% of BMY.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $66.06; ratings include one Strong Buy, 13 Buys, 10 Holds and one Sell.
• Bristol Myers Squibb beat quarterly earnings and revenue estimates, reporting $2.04 in EPS and $12.97 billion in revenue. The company also pays a $0.63 quarterly dividend, equivalent to a 3.8% yield.

Munich Reinsurance Co Stock Corp in Munich lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 9.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 347,582 shares of the biopharmaceutical company's stock after purchasing an additional 31,048 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich's holdings in Bristol Myers Squibb were worth $20,028,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. boosted its position in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the period. State Street Corp increased its position in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company's stock worth $5,285,065,000 after acquiring an additional 1,385,206 shares during the period. Geode Capital Management LLC raised its stake in shares of Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Norges Bank purchased a new position in Bristol Myers Squibb in the fourth quarter valued at $1,947,272,000. Finally, AQR Capital Management LLC boosted its holdings in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock valued at $1,391,485,000 after purchasing an additional 16,332,924 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BMY. Raymond James Financial started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "strong-buy" rating on the stock. Roth Capital initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price objective for the company. Royal Bank Of Canada boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a research report on Friday, July 31st. JPMorgan Chase & Co. upped their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Finally, Citigroup reaffirmed a "neutral" rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $66.06.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $66.85 on Friday. The stock has a 50 day moving average price of $62.92 and a 200 day moving average price of $59.92. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $136.56 billion, a price-to-earnings ratio of 14.72, a price-to-earnings-growth ratio of 0.32 and a beta of 0.23. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm's revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a Phase 2 trial evaluating a therapy in depression, expanding its pipeline into a large potential market. Positive clinical progress could provide a new growth opportunity if the treatment demonstrates efficacy and safety. Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, roughly 3.7% forward dividend yield, strong margins and growth products that are offsetting declines in older medicines. These factors support the stock’s defensive and income-oriented appeal. Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
• Neutral Sentiment: Technical indicators have reportedly turned bullish, while RBC Capital maintained a Hold rating, indicating that analysts see some upside but remain cautious about the company’s outlook. Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
• Negative Sentiment: Bristol Myers Squibb paused enrollment in its zola-cel autoimmune cell-therapy trials after safety surveillance identified inflammatory side effects. Reports that the pause involved serious safety concerns raised questions about the program’s risk profile, development timeline and broader cell-therapy strategy. What Does Bristol Myers Squibb Trial Pause Mean For Its Pipeline?
• Negative Sentiment: The wider healthcare sector traded lower, adding industry-level pressure to BMY. Investors also continue to monitor legacy-drug declines, including Opdivo, and future Eliquis patent-expiry risks. Sector Update: Healthcare Stocks Decline Friday Afternoon

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source